Mauro Ceroni

Mauro Ceroni

Auto-generated profile, based on publicly available information

Mauro Ceroni

Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Neuron
Verified
Journal Article
Closed access
BSBradley N. Smith
Bradley N. Smith
NTNicola Ticozzi
Nicola Ticozzi
CFClaudia Fallini
Claudia Fallini
AGAthina Soragia Gkazi
Athina Soragia Gkazi
STSimon Topp
Simon Topp
CBCinzia Bertolin
Cinzia Bertolin

13 March 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SGStefania Guareschi
Stefania Guareschi
ECEmanuela Cova
Emanuela Cova
CCCristina Cereda
Cristina Cereda
MCMauro Ceroni
Mauro Ceroni
EDElena Donetti
Elena Donetti
PPPiera Pasinelli
Piera Pasinelli
Recent studies suggest that Cu/Zn superoxide dismutase (SOD1) could be pathogenic in both familial and sporadic amyotrophic lateral sclerosis (ALS) through either inheritable or nonheritable modifications. The presence of a misfolded WT SOD1 in patients with sporadic ALS, along with the recently reported evidence that reducing SOD1 levels in astrocytes derived from sporadic patients inhibits astrocyte-mediated toxicity on motor neurons, suggest that WT SOD1 may acquire toxic properties similar to familial ALS-linked mutant SOD1, perhaps through posttranslational modifications. Using patients’ lymphoblasts, we show here that indeed WT SOD1 is modified posttranslationally in sporadic ALS and is iper-oxidized (i.e., above baseline oxidation levels) in a subset of patients with bulbar onset. Derivatization analysis of oxidized carbonyl compounds performed on immunoprecipitated SOD1 identified an iper-oxidized SOD1 that recapitulates mutant SOD1-like properties and damages mitochondria by forming a toxic complex with mitochondrial Bcl-2. This study conclusively demonstrates the existence of an iper-oxidized SOD1 with toxic properties in patient-derived cells and identifies a common SOD1-dependent toxicity between mutant SOD1-linked familial ALS and a subset of sporadic ALS, providing an opportunity to develop biomarkers to subclassify ALS and devise SOD1-based therapies that go beyond the small group of patients with mutant SOD1.

1 December 2005 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Angelica FacoettiAngelica Facoetti
Angelica Facoetti
RNRosanna Nano
Rosanna Nano
PZPaola Zelini
Paola Zelini
PMPatrizia Morbini
Patrizia Morbini
EBEugenio Benericetti
Eugenio Benericetti
SFSoldano Ferrone
Soldano Ferrone
Purpose: To determine the frequency of abnormalities in human leukocyte antigen (HLA) and antigen processing machinery (APM) component expression in malignant brain tumors. This information may contribute to our understanding of the immune escape mechanisms used by malignant brain tumors because HLA antigens mediate interactions of tumor cells with the host's immune system.

1 October 2002 in Pharmacogenetics
Verified
Journal Article
Closed access
TFTaku Furuno
Taku Furuno
MLMaria-Teresa Landi
Maria-Teresa Landi
MCMauro Ceroni
Mauro Ceroni
NCNeil Caporaso
Neil Caporaso
IBIlaria Bernucci
Ilaria Bernucci
UZUlrich M. Zanger
Ulrich M. Zanger
Because drug transporters such as P-glycoprotein, the product of the multidrug resistance (MDR1) gene, contribute to the function of the blood–brain barrier, we hypothesized that differences in their expression could affect the uptake of neurotoxic xenobiotics, thereby modulating interindividual susceptibility for neurological disorders such as Parkinson's disease. In a pilot case–control study comprising 95 Parkinson's disease patients (25 early-onset patients with onset age ≤ 45 years) and 106 controls we analysed the three common MDR1 polymorphisms, 3435C > T in exon 26, 2677G > T,A in exon 21, and −129T > C in exon 1b. There were no statistically significant associations between any of these polymorphisms and Parkinson's disease. However, a distribution pattern consistent with our hypothesis was observed in that the frequency of the 3435T/T genotype, which had previously been associated with decreased P-glycoprotein expression and function, was highest in the early-onset Parkinson's disease group (36.0%), second-highest in the late-onset Parkinson's disease group (22.9%), and lowest in the control group (18.9%). Furthermore, we confirmed that the MDR1 exon 21 and exon 26 polymorphisms are in significant linkage disequilibrium since the [2677G, 3435C] and [2677T, 3435T] haplotypes were far more frequently observed than expected. In conclusion, MDR1 and other drug transporters represent plausible candidates as Parkinson's disease risk genes. Larger studies are required to confirm this role in the etiology of Parkinson's disease.

26 October 2009 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
LCLucia Corrado
Lucia Corrado
RBRoberto Del Bo
Roberto Del Bo
BCBARBARA CASTELLOTTI
BARBARA CASTELLOTTI
ARAntonia Ratti
Antonia Ratti
CCCristina Cereda
Cristina Cereda
VSVincenzo Silani
Vincenzo Silani
Background: Mutations in the FUS gene have recently been discovered to be a major cause of familial amyotrophic lateral sclerosis (FALS). Objective: To determine the identity and frequency of FUS gene mutations in a large cohort of Italian patients enriched in sporadic cases (SALS). Methods: Exons 5, 6, 14 and 15 of the FUS gene were screened for mutations in 1009 patients (45 FALS and 964 SALS). The genetic analysis was extended to the entire coding sequence of FUS in all the FALS and 293 of the SALS patients. Results: Seven missense mutations (p.G191S, p.R216C, p.G225V, p.G230C, p.R234C, p.G507D and p.R521C) were identified in nine patients (seven SALS and two FALS), and none in 500 healthy Italian controls. All mutations are novel except for the p.R521C mutation identified in one SALS and one FALS case. Both patients showed a similar unusual presentation, with proximal, mostly symmetrical, upper limb weakness, with neck and axial involvement. With the exception of p.G507D and p.R521C, the mutations identified in SALS patients are all localised in the glycine-rich region encoded by exon 6. In addition, eight different in-frame deletions in two polyglycine motifs were detected, the frequency of which was not significantly different in patients and controls. Conclusions: The results show that FUS missense mutations are present in 0.7% of Italian SALS cases, and confirm the previous mutational frequency reported in FALS (4.4%). An unusual proximal and axial clinical presentation seems to be associated with the presence of the p.R521C mutation.

20 November 2013 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
IFIsabella Fogh
Isabella Fogh
ARAntonia Ratti
Antonia Ratti
CGCinzia Gellera
Cinzia Gellera
KLKuang Lin
Kuang Lin
CTCinzia Tiloca
Cinzia Tiloca
JZJ. G. Zheng
J. G. Zheng
Identification of mutations at familial loci for amyotrophic lateral sclerosis (ALS) has provided novel insights into the aetiology of this rapidly progressing fatal neurodegenerative disease. However, genome-wide association studies (GWAS) of the more common (∼90%) sporadic form have been less successful with the exception of the replicated locus at 9p21.2. To identify new loci associated with disease susceptibility, we have established the largest association study in ALS to date and undertaken a GWAS meta-analytical study combining 3959 newly genotyped Italian individuals (1982 cases and 1977 controls) collected by SLAGEN (Italian Consortium for the Genetics of ALS) together with samples from Netherlands, USA, UK, Sweden, Belgium, France, Ireland and Italy collected by ALSGEN (the International Consortium on Amyotrophic Lateral Sclerosis Genetics). We analysed a total of 13 225 individuals, 6100 cases and 7125 controls for almost 7 million single-nucleotide polymorphisms (SNPs). We identified a novel locus with genome-wide significance at 17q11.2 (rs34517613 with P = 1.11 × 10−8; OR 0.82) that was validated when combined with genotype data from a replication cohort (P = 8.62 × 10−9; OR 0.833) of 4656 individuals. Furthermore, we confirmed the previously reported association at 9p21.2 (rs3849943 with P = 7.69 × 10−9; OR 1.16). Finally, we estimated the contribution of common variation to heritability of sporadic ALS as ∼12% using a linear mixed model accounting for all SNPs. Our results provide an insight into the genetic structure of sporadic ALS, confirming that common variation contributes to risk and that sufficiently powered studies can identify novel susceptibility loci.